Volastra Therapeutics

We’re thrilled to welcome our co-founder, @Samuel_Bakhoum, M.D., Ph.D., to the Volastra team as CSO! Dr. Bakhoum is a renowned physician-scientist & leader in #cancer research, who has pioneered work in the field of #chromosomal_instability (CIN).
bit.ly/3UetqMW

Pleased to share that our CEO, David Southwell, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept 9. We’ll discuss our clinical-stage KIF18A inhibitors and mission to develop novel cancer therapeutics.

#Oncology #Biotech #CIN

A proud moment at #ASCO25: data from the dose escalation portion of our Phase I/II study for our novel #KIF18A inhibitor, VLS-1488, earned a spot at the podium.

This milestone reflects the momentum behind #KIF18A inhibition and the dedication of our team and partners.

Volastra is thrilled to share encouraging initial data from the dose escalation portion of our Phase I/II trial of our novel #KIF18A inhibitor, VLS-1488, at #ASCO2025 in Chicago.

More details here: volastratx.com/initial-data-f…

On #WorldOvarianCancerDay, we honor the patients, families & communities affected by this devastating disease. Their stories drive our mission at Volastra—to bring new treatment options to those who need them most. #WOCD2025